![Video Image: NewsObserver.com](/images/HempNorthCarolinaVideoImageNewsObserverDotCom.jpg)
RALEIGH - The state commission charged with fostering an industrial hemp industry in North Carolina is considering joining a lawsuit against a government agency that it agrees is making things difficult: the U.S. Drug Enforcement Administration.
RALEIGH - The state commission charged with fostering an industrial hemp industry in North Carolina is considering joining a lawsuit against a government agency that it agrees is making things difficult: the U.S. Drug Enforcement Administration.
RALEIGH - The state commission charged with fostering an industrial hemp industry in North Carolina is considering joining a lawsuit against a government agency that it agrees is making things difficult: the U.S. Drug Enforcement Administration.
The Drug Enforcement Administration announced Thursday that it is ending the federal government’s decades-long monopoly on cultivation of marijuana for research purposes, a move that is expected to usher in more scientific analysis of the plant’s medical benefits.
The Drug Enforcement Administration announced Thursday that it is ending the federal government’s decades-long monopoly on cultivation of marijuana for research purposes, a move that is expected to usher in more scientific analysis of the plant’s medical benefits.
Bruce Kennedy ~ WeedWorthy.com ~
A group of U.S. lawmakers is calling on the U.S. Drug Enforcement Administration (DEA) of remove federal barriers on medical marijuana research and to ease new medical research on cannabis and its derivatives.
Sen. Elizabeth Warren has signed on to a letter asking the U.S. Department of Justice and the Drug Enforcement Administration for an update on the agencies' decision about whether they plan to change marijuana's classification at the federal level. Marijuana is currently classified as a "Schedule I" drug under the Controlled Substances Act.
Copyright 2019 - 2024. WeedWorthy.com is a news division of MjLink.com, Inc.. All rights reserved. WeedWorthy
To contact the following departments, dial 1-844-420-4208 - Sales: Ext. #2 - Support: Ext. #3 - Investor Relations: Ext. #6
By using this website, you agree and understand that, by law: You MUST be at least 21 years of age to view any content on this website. To view the complete Terms of Use and Privacy Policy for this website, Click Here!